Convalescent plasma therapy for COVID-19: a review of old therapy against new disease


  • Utshav Chapagain Department of Clinical Pharmacology and Therapeutics, B P Koirala Institute of Health Sciences, Dharan, Nepal
  • Gajendra Prasad Raunair Department of Clinical Pharmacology and Therapeutics, B P Koirala Institute of Health Sciences, Dharan, Nepal
  • Kumud Chapagain Department of Clinical Pharmacology and Therapeutics, B P Koirala Institute of Health Sciences, Dharan, Nepal
  • Rakesh Verma Department of Clinical Pharmacology and Therapeutics, B P Koirala Institute of Health Sciences, Dharan, Nepal



Antibodies, COVID-19, Convalescent plasma therapy, SARS-CoV-2


Currently, novel coronavirus disease 2019 (COVID-19) is a big threat to global health which has revived the potential beneficial effect of ancient convalescent plasma therapy (CPT). This review was conducted to evaluate the effectiveness and adverse drug reactions associated with convalescent plasma therapy in COVID-19 patients, based on articles available to date. PubMed, Google Scholar, Cochrane library, and Hinari databases were searched until 15th September 2020. Every country across the globe today is encountered with a virus that has impacted millions of lives today and for generations to come. Nonetheless recommended antiviral drugs and vaccines are not evident and specified for novel coronavirus disease. This is now very well known that scientists and medical experts across the world are vigilant about recommending the use of CPT and call it an investigational treatment that may help in assisting recovery. The World health organization has perpetuated that there is not enough proof that plasma therapy works in treating those fighting the novel coronavirus. Therefore, convalescent plasma therapy is a feasible and immediate option for alleviating the impact of the disease. Comparing the effectiveness of convalescent plasma therapy with SARS-CoV, MERS-CoV, and COVID-19 would help in deriving proper outcomes for COVID-19 infected cases.


Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323(11):1061-9.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020;323(13):1239-42.

World Health Organization. Coronavirus disease 2019 (COVID‐19) ‐Situation Report ‐ 90 (September 15, 2020). Available at:‐coronavirus‐2019/situation‐reports. Accessed on 15 September 2020.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 8]. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing. 2020.

Jonathan Forani. CORONAVIRUS. Available at: Accessed on 24 August 2020.

Casadevall A, Pirofski LA. The convalescent sera option for containing COVID‐19. J Clin Invest. 2020;130(4):1545‐8.

Center for Biologics Evaluation and Research. Investigational COVID-19 convalescent plasma - Emergency INDs 26 March 2020. Available at: Accessed on 20 September 2020.

Behring Ev. Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. 2013.

Moore JJ. The Action of Vaccines and of Concentrated Antistreptococcus Serum in Experimental Streptococcal Arthritis. J Infect Dis. 1914;15(1):215-26.

Smith DD. Serum treatment of scarlet fever [doctoral thesis]. Omaha (Nebraska): University of Nebraska; 1934.

Lewis JM, Barenberg LH. The use of convalescent serum in the treatment of measles, chickenpox, mumps and whooping cough, including the prophylactic value of parental blood. State J Med. 1933;33:2.

Kohn JL, Klein IF, Schwarz H. Treatment of pre eruptive measles with convalescent serum. J Am Med Assoc. 1938;111(26):2361–4.

Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy. 1994;38(8):1695-702.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-6.

Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791-7.

Montelongo-Jauregui D, Vila T, Sultan AS, Jabra-Rizk. Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease. PLoS Pathog. 2020;16(8):e1008735.

Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.

Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1.

Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-56.

Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-22.

Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365-7.

Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400.

Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2013;369(4):394.

Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect. 2013;67(2):130-40.

ISARIC, International Severe Acute Respiratory & Emerging Infection Consor-tium. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.0, 18 June, 2013. Available at: 1317139281416. Accessed on 26 July 2020.

Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-65.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yang J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. J Am Med Assoc. 2020;323(16):1582-9.

Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. J Am Med Assoc. 2020;323(16):1561-2.

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. J Am Med Assoc. 2020;324(5):460-70.

Casadevall A, Joyner MJ, Pirofski L. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals. J Am Med Assoc. 2020;324(5):455-7.

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bio Med J. 2020:371.




How to Cite

Chapagain, U., Raunair, G. P., Chapagain, K., & Verma, R. (2020). Convalescent plasma therapy for COVID-19: a review of old therapy against new disease. International Journal of Basic & Clinical Pharmacology, 9(12), 1909–1916.



Review Articles